溶瘤病毒和基于细胞因子的基因疗法重新编程肿瘤微环境。

IF 28.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2026-04-24 DOI:10.1038/s43018-026-01153-y

Joshua D Bernstock, Lennard Spanehl, E Antonio Chiocca

{"title":"溶瘤病毒和基于细胞因子的基因疗法重新编程肿瘤微环境。","authors":"Joshua D Bernstock, Lennard Spanehl, E Antonio Chiocca","doi":"10.1038/s43018-026-01153-y","DOIUrl":null,"url":null,"abstract":"Solid tumors are sustained by profoundly immunosuppressive tumor microenvironments (TMEs) that underlie resistance to immunotherapy. Engineered oncolytic viruses and cytokine-based gene therapies can reprogram the TME, converting 'cold' tumors into immune-responsive states and amplifying antitumor immunity. Several agents have achieved regulatory approval, and clinical studies demonstrate that even limited dosing can induce durable changes in immune infiltration and cytokine signaling. Yet consistent and lasting clinical responses remain elusive. Here, we synthesize translational insights from recent trials and highlight emerging strategies to overcome barriers and enhance the therapeutic impact of these TME-modulating biologics.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":" ","pages":""},"PeriodicalIF":28.5000,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment.\",\"authors\":\"Joshua D Bernstock, Lennard Spanehl, E Antonio Chiocca\",\"doi\":\"10.1038/s43018-026-01153-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Solid tumors are sustained by profoundly immunosuppressive tumor microenvironments (TMEs) that underlie resistance to immunotherapy. Engineered oncolytic viruses and cytokine-based gene therapies can reprogram the TME, converting 'cold' tumors into immune-responsive states and amplifying antitumor immunity. Several agents have achieved regulatory approval, and clinical studies demonstrate that even limited dosing can induce durable changes in immune infiltration and cytokine signaling. Yet consistent and lasting clinical responses remain elusive. Here, we synthesize translational insights from recent trials and highlight emerging strategies to overcome barriers and enhance the therapeutic impact of these TME-modulating biologics.\",\"PeriodicalId\":18885,\"journal\":{\"name\":\"Nature cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":28.5000,\"publicationDate\":\"2026-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s43018-026-01153-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s43018-026-01153-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

实体肿瘤是由深度免疫抑制肿瘤微环境（TMEs）维持的，这是免疫治疗耐药的基础。工程溶瘤病毒和基于细胞因子的基因疗法可以重新编程TME，将“冷”肿瘤转化为免疫应答状态，并增强抗肿瘤免疫。一些药物已经获得了监管部门的批准，临床研究表明，即使是有限的剂量也可以诱导免疫浸润和细胞因子信号传导的持久变化。然而，一致和持久的临床反应仍然难以捉摸。在这里，我们综合了来自最近试验的翻译见解，并强调了克服障碍和增强这些tme调节生物制剂治疗效果的新兴策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment.

Solid tumors are sustained by profoundly immunosuppressive tumor microenvironments (TMEs) that underlie resistance to immunotherapy. Engineered oncolytic viruses and cytokine-based gene therapies can reprogram the TME, converting 'cold' tumors into immune-responsive states and amplifying antitumor immunity. Several agents have achieved regulatory approval, and clinical studies demonstrate that even limited dosing can induce durable changes in immune infiltration and cytokine signaling. Yet consistent and lasting clinical responses remain elusive. Here, we synthesize translational insights from recent trials and highlight emerging strategies to overcome barriers and enhance the therapeutic impact of these TME-modulating biologics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.